First Hawaiian Bank reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 12,459 shares of the medical research company’s stock after selling 593 shares during the period. First Hawaiian Bank’s holdings in Thermo Fisher Scientific were worth $2,788,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. IMS Capital Management bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $53,000. Cornerstone Advisors Inc. increased its position in shares of Thermo Fisher Scientific by 33.3% during the third quarter. Cornerstone Advisors Inc. now owns 332 shares of the medical research company’s stock valued at $81,000 after buying an additional 83 shares during the period. Banco de Sabadell S.A bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $122,000. Prime Capital Investment Advisors LLC increased its position in shares of Thermo Fisher Scientific by 396.0% during the third quarter. Prime Capital Investment Advisors LLC now owns 620 shares of the medical research company’s stock valued at $151,000 after buying an additional 495 shares during the period. Finally, Atlantic Trust LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $154,000. Institutional investors and hedge funds own 86.92% of the company’s stock.

Shares of TMO opened at $238.86 on Friday. The company has a market capitalization of $95.17 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 1.54 and a beta of 1.08. The company has a quick ratio of 1.27, a current ratio of 1.84 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a 1 year low of $194.51 and a 1 year high of $253.91.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.55 by $0.07. The business had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.70 billion. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. Thermo Fisher Scientific’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.31 earnings per share. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 11.05 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th will be given a $0.17 dividend. The ex-dividend date is Friday, December 14th. This represents a $0.68 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is currently 7.17%.

TMO has been the subject of several recent analyst reports. UBS Group initiated coverage on Thermo Fisher Scientific in a report on Tuesday, October 9th. They set a “buy” rating and a $295.00 price objective for the company. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Thursday, December 6th. Goldman Sachs Group lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Monday, September 17th. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $254.00 to $260.00 and gave the stock an “overweight” rating in a report on Thursday, October 25th. Finally, Robert W. Baird boosted their price objective on Thermo Fisher Scientific from $256.00 to $264.00 and gave the stock an “outperform” rating in a report on Thursday, October 25th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $271.10.

In related news, Director Tyler Jacks sold 1,100 shares of the company’s stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $251.98, for a total transaction of $277,178.00. Following the completion of the transaction, the director now owns 5,879 shares in the company, valued at $1,481,390.42. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Stephen Williamson sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, December 7th. The shares were sold at an average price of $241.45, for a total value of $2,293,775.00. Following the transaction, the chief financial officer now owns 44,124 shares of the company’s stock, valued at approximately $10,653,739.80. The disclosure for this sale can be found here. Insiders sold 32,607 shares of company stock valued at $7,972,085 in the last quarter. Corporate insiders own 0.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://theolympiareport.com/2019/01/11/first-hawaiian-bank-lowers-position-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: How much can an individual set aside as a catch-up contribution?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.